RayKnowChina Research Map
Shortlist

Ningbo

Ningbo Medical Center Lihuili Hospital

宁波市医疗中心李惠利医院

Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Ningbo Medical Center Lihuili Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led
  3. Hepatocellular carcinoma肝细胞癌31 papers led1 open trial led
  4. Stomach cancer胃癌17 papers led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Myasthenia gravis重症肌无力1 paper led
  8. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  9. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  10. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 3320242025: 002025

2 hospitals in Ningbo for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Radiotherapy Combined With Endostatin and Capecitabine for NPC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05514275

    Age 18 years to 65 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

  2. Recruiting
    Immune Score Based Radiomics in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05126160

    Age 18 years to 70 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 4 listed hospitals as study sitesHangzhou, Ningbo, Wenzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapy
Departments in papersENT / head & neck surgeryRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led8
  1. SELENBP1 Inhibits the Malignant Progression and Radioresistance of Nasopharyngeal Carcinoma Cells Through the KEAP1-NRF2 Signaling Pathway.2026Biochemical genetics
  2. Global epidemiological profile in nasopharyngeal carcinoma: a prediction study.2024BMJ openFree full text
  3. Exosome-Mediated Transfer of ALDH2 in Nasopharyngeal Carcinoma Cells Confers Increased Resistance to Paclitaxel Treatment.2024Discovery medicine
  4. Exploring Programmed Cell Death-Related Biomarkers and Disease Therapy Strategy in Nasopharyngeal Carcinoma Using Transcriptomics.2024Frontiers in bioscience (Landmark edition)
  5. Knockdown of FKBP3 suppresses nasopharyngeal carcinoma cell growth, invasion and migration, deactivated NF-κB/IL-6 signaling pathway through inhibiting histone deacetylase 2 expression.2023The Chinese journal of physiology
  6. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990-2019.2022Acta oto-laryngologica
  7. The effect of combined TPF and intensity modulated radiotherapy after TPF induction chemotherapy on locally advanced nasopharyngeal carcinoma: a retrospective analysis.2021Annals of palliative medicine
  8. Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database.2021Oral oncology
Chinese-language papers (not in the count)1
  1. [Hinokiol regulates the cell cycle and apoptosis of nasopharyngeal carcinoma CNE1 cells via Hippo-YAP signaling pathway].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status2
  1. Radiotherapy Combined With Endostatin and Capecitabine for NPCRecruitingNCT05514275Study sitePhase 2Start 2022-08
  2. Immune Score Based Radiomics in Nasopharyngeal CarcinomaRecruitingNCT05126160Study siteStart 2021-11
More papers found outside PubMed (not counted)4
  1. WITHDRAWN: Newly insight into the pathogenesis of nasopharyngeal carcinoma through a series of bioinformatic analysis2023Oral Oncology Reportsretraction
  2. The global, regional, and national burden of nasopharyngeal carcinoma and its attributable risk factors in 204 countries and territories, 1990–20192022Figsharedataset
  3. Preparation of Magnetic Drug Loaded Nanoparticles and Its Anticancer Efficacy Against Nasopharyngeal Carcinoma Cells2021Science of Advanced Materialsarticle
  4. Role of TGF-β/Smad Signaling Pathway-Related Proteins in Clinicopathological Features and Prognosis and Survival of Patients with Nasopharyngeal Carcinoma2021Molecular Biology & Nanomedicinearticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 4420242025: 222025

2 hospitals in Ningbo for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
    Phase
    Phase 2
    Started
    2022-08
    Registry
    NCT05507411

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer Hospital; 2 listed hospitals as study sitesHangzhou, Ningbo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentSurgeryRadiotherapy
Departments in papersGastroenterology / hepatologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led8
  1. Macrophage efferocytosis mediated by the TP63-RAC2 pathway promotes immunosuppressive remodeling in esophageal cancer.2026Cell reports. MedicineFree full text
  2. Upregulation of has_circ_0008389 promotes esophageal squamous cell carcinoma progression via miR-761 sponging and P2RY2 mRNA stabilization.2025International journal of biological macromolecules
  3. Perioperative outcomes following neoadjuvant immunochemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma.2025The Journal of international medical researchFree full text
  4. ASO Author Reflections: COL8A1 Regulates Esophageal Squamous Carcinoma.2024Annals of surgical oncology
  5. Circ_0023990 Promotes the Proliferation, Invasion, and Glycolysis of Esophageal Squamous Cell Carcinoma Cells Via Targeting miR-6884-5p/PAK1 Axis.2024Biochemical genetics
  6. circ_0000592 facilitates the progression of esophageal squamous cell carcinoma via miR-155-5p/FZD5 axis.2024Journal of biochemical and molecular toxicology
  7. A retrospective cohort study to observe the efficacy and safety of Endoscopic Submucosal Dissection (ESD) with adjuvant radiotherapy for T1a-MM/T1b-SM Esophageal Squamous Cell Carcinoma (ESCC).2024PloS oneFree full text
  8. Upregulation of hsa_circ_0000977 participates in esophageal squamous cancer progression by sponging miR-874-3p.2022Journal of clinical laboratory analysisFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCCRecruitingNCT05507411Study sitePhase 2Start 2022-08
More papers found outside PubMed (not counted)1
  1. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 31 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
31
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 6620232024: 7720242025: 992025

2 hospitals in Ningbo for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07368023

    Age 16 years to Not stated (registered criteria)

    Led by Ningbo Medical Center Lihuili HospitalNingbo

  2. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  3. Not yet recruiting
    Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07553767

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNingbo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionSurgery & liver transplant
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiation oncologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led31
  1. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.2025Annals of medicineFree full text
  2. Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  3. LZTR1 expression as a novel predictive biomarker for early recurrence of hepatocellular carcinoma.2025European journal of medical researchFree full text
  4. Nanomaterial-assisted immunodiagnostic profiling and therapeutic targeting of hepatocellular carcinoma: from molecular biomarkers to clinical applications.2025Frontiers in immunologyFree full text
  5. Prognostic Value of Inflammatory Markers in HBV-Related HCC After Hepatectomy Based on a Clinical Database.2025Journal of investigative surgery : the official journal of the Academy of Surgical Research
  6. Enhancing deep-seated hepatocellular carcinoma detection: assessing the added value of high mechanical index setting in sonazoid-based contrast-enhanced ultrasound during post-vascular phase.2025Journal of medical ultrasonics (2001)
  7. Ubiquitination in hepatocellular carcinoma immunity.2025Journal of translational medicineFree full text
  8. Exploring the double-edged role of cellular senescence in chronic liver disease for new treatment approaches.2025Life sciences
  9. PLD2 is a marker for MASLD-HCC with early-stage fibrosis: revealed by lipidomic and gene expression analysis.2025Metabolomics : Official journal of the Metabolomic Society
  10. CDCA7 serves as a novel prognostic marker in human hepatocellular carcinoma.2024Biotechnology & genetic engineering reviews
  11. Impact of anesthesia-related genes on prognosis and tumor microenvironment in hepatocellular carcinoma: A comprehensive analysis.2024Environmental toxicology
  12. Developing a prognostic model for hepatocellular carcinoma based on MED19 and clinical stage and determining MED19 as a therapeutic target.2024Journal of cancer research and clinical oncologyFree full text
  13. Development of a novel lncRNA-derived immune gene score using machine learning-based ensembles for predicting the survival of HCC.2024Journal of cancer research and clinical oncologyFree full text
  14. A Comparative Study of Laparoscopic and Open Approaches for Right Hemihepatectomy in Hepatocellular Carcinoma Patients: Safety and Short-Term Outcomes.2024Medical science monitor : international medical journal of experimental and clinical researchFree full text
  15. CircSNX6 promotes proliferation, metastasis, and angiogenesis in hepatocellular carcinoma via miR-383-5p/VEGFA signaling pathway.2024Scientific reportsFree full text
  16. Non-surgery strategy versus hepatectomy in hepatocellular carcinoma patients with complete response after conversion therapy: a meta-analysis.2024World journal of surgical oncologyFree full text
  17. Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients.2023Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  18. MTM-HCC at Previous Liver Resection as a Predictor of Overall Survival in Salvage Liver Transplantation.2023Digestive diseases and sciences
  19. Macrotrabecular-massive subtype-based nomogram to predict early recurrence of hepatocellular carcinoma after surgery.2023European journal of gastroenterology & hepatologyFree full text
  20. A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  21. Application of adoptive cell therapy in hepatocellular carcinoma.2023Immunology
  22. Global trends of targeted therapy for hepatocellular carcinoma: A bibliometric and visualized study from 2008 to 2022.2023MedicineFree full text
  23. IGF-1 contributes to liver cancer development in diabetes patients by promoting autophagy.2022Annals of hepatology
  24. Development of nomogram models of inflammatory markers based on clinical database to predict prognosis for hepatocellular carcinoma after surgical resection.2022BMC cancerFree full text
  25. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.2022Cell death & diseaseFree full text
  26. Predictive Value of the TP53 p.G245S Mutation Frequency for the Short-Term Recurrence of Hepatocellular Carcinoma as Detected by Pyrophosphate Sequencing.2022Genetic testing and molecular biomarkers
  27. Comprehensive bioinformatic analysis of MMP1 in hepatocellular carcinoma and establishment of relevant prognostic model.2022Scientific reportsFree full text
  28. Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.2022Scientific reportsFree full text
  29. CircFOXM1 promotes proliferation and metastasis of hepatocellular carcinoma via regulating miR-1179/SPAG5 axis.2021Scientific reportsFree full text
  30. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.2021Scientific reportsFree full text
  31. Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma.2021Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. [Analysis of strong invasive clinical features and poor prognosis in macrotrabecular-massive hepatocellular carcinoma].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07368023Lead sponsorStart 2026-01
  2. Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionNot yet recruitingNCT07553767Study siteEarly phase 1Start 2026-03
  3. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  4. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 5520222023: 5520232024: 2220242025: 552025

4 hospitals in Ningbo for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05970627

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryChemotherapy & combined treatment
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiation oncologyPathology / laboratory medicineGastroenterology / hepatology
Papers it led17
  1. RBM15 promotes lipogenesis and malignancy in gastric cancer by regulating N6-Methyladenosine modification of ACLY mRNA in an IGF2BP2-dependent manner.2025Biochimica et biophysica acta. Molecular and cell biology of lipids
  2. Bone Metastasis Mediates Poor Prognosis in Early-Onset Gastric Cancer: Insights Into Immune Suppression, Coagulopathy, and Inflammation.2025Cancer medicineFree full text
  3. Perioperative immunotherapy in gastric cancer: walking a fine line between hope and caution.2025Frontiers in immunologyFree full text
  4. Relationship between creatine kinase and gastric cancer: A two-sample Mendelian randomization study.2025MedicineFree full text
  5. Risk analysis of jejunal orientation on the incidence of dysphagia after total gastrectomy: a retrospective cohort study.2025Surgical endoscopyFree full text
  6. Helicobacter pylori CagA protein induces gastric cancer stem cell-like properties through the Akt/FOXO3a axis.2024Journal of cellular biochemistry
  7. Comparison Between Billroth II and Billroth II + Braun Anastomosis in Gastrectomy for Gastric Cancer.2024The Journal of surgical research
  8. Convenient method to improve efficiency of lymph node examination after gastrectomy with D2 lymphadenectomy for gastric cancer.2023BMC gastroenterologyFree full text
  9. Integrated Single-Cell and Transcriptome Sequencing Analyses Develop a Ubiquitination-Associated Signature in Gastric Cancer and Identified OTULIN as a Novel Biomarker.2023Frontiers in bioscience (Landmark edition)
  10. LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  11. Comprehensive Analysis to Reveal Amino Acid Metabolism-Associated Genes as a Prognostic Index in Gastric Cancer.2023Mediators of inflammationFree full text
  12. Data-independent acquisition (DIA) mass spectrometry reveals related proteins involved in the occurrence of early intestinal-type gastric cancer.2023Medical oncology (Northwood, London, England)
  13. LncRNA MBNL1-AS1 represses gastric cancer progression via the TGF-β pathway by modulating miR-424-5p/Smad7 axis.2022BioengineeredFree full text
  14. Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway.2022Cell biology internationalFree full text
  15. Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing JAK/STAT3 signaling pathway.2022Drug development research
  16. Overexpression of Copines-1 is associated with clinicopathological parameters and poor outcome in gastric cancer.2022Journal of clinical laboratory analysisFree full text
  17. High COL10A1 expression potentially contributes to poor outcomes in gastric cancer with the help of LEF1 and Wnt2.2022Journal of clinical laboratory analysisFree full text
Chinese-language papers (not in the count)1
  1. Prediction of peritoneal free cancer cells in gastric cancer patients by golden-angle radial sampling dynamic contrast-enhanced magnetic resonance imaging.2024Journal of Zhejiang University. Science. BFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaNot yet recruitingNCT05970627Study sitePhase 2Start 2023-07
  2. Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaActive, not recruitingNCT05715931Study sitePhase 2Start 2023-05
  3. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric CarcinomaCompletedNCT01364376Study siteN/AStart 2011-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

14 hospitals in Ningbo for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Ningbo for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Ningbo for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesBiologic & complement drugsAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Ningbo for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Ningbo for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Ningbo for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

宁波市医疗中心李惠利医院

Ningbo Medical Center Lihuili Hospital

宁波

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Affiliated Lihuili Hospital; Ningbo Medical Centre Lihuili Hospital; Affiliated Lihuili Hospital of Ningbo University; Lihuili Hospital; Ningbo Medical Center Lihuili Eastern Hospital; Lihuili Hospital Affiliated to Ningbo University; Ningbo City Medical Center Lihuili Hospital

Suggest a correctionDownload the data